Search results
Results from the WOW.Com Content Network
In the first year of treatment, the rate of growth may increase from half as fast as other children are growing to twice as fast (e.g., from 1 inch a year to 4 inches, or 2.5 cm to 10). Growth typically slows in subsequent years, but usually remains above normal so that over several years a child who had fallen far behind in their height may ...
Laron syndrome (LS), also known as growth hormone insensitivity or growth hormone receptor deficiency (GHRD), is an autosomal recessive disorder characterized by a lack of insulin-like growth factor 1 (IGF-1; somatomedin-C) production in response to growth hormone (GH; hGH; somatotropin). [6]
Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical ...
Isolated growth hormone deficiency (IGHD) is a rare congenital disorder characterized by growth hormone deficiency and postnatal growth failure. [ 2 ] [ 3 ] It is divided into four subtypes that vary in terms of cause and clinical presentation.
Psychosocial short stature (PSS) is a growth disorder that is observed between the ages of 2 and 15, caused by extreme emotional deprivation or stress.. The symptoms include decreased growth hormone (GH) and somatomedin secretion, very short stature, weight that is inappropriate for the height, and immature skeletal age.
Despite the apparent necessity of GH/IGF-1 signaling in pubertal breast development however, women with Laron syndrome, in whom the growth hormone receptor (GHR) is defective and insensitive to GH and serum IGF-1 levels are very low, puberty, including breast development, is delayed, although full sexual maturity is always eventually reached. [15]
National Cooperative Growth Study (NCGS) is the largest observational database in the U.S. of children with growth disorders. Started in 1985, NCGS was a long term longitudinal study following patients undergoing growth hormone treatment in North America (the U.S. and Canada).
Linear growth is a complex process regulated by the growth hormone (GH) – insulin-like growth factor-1 axis, the thyroxine/triiodothyronine axis, androgens, estrogens, vitamin D, glucocorticoids and possibly leptin. [25] GH is secreted by the anterior pituitary gland in response to hypothalamic, pituitary and circulating factors.